» Articles » PMID: 32498248

Ubiquinol-10 Intake Is Effective in Relieving Mild Fatigue in Healthy Individuals

Overview
Journal Nutrients
Date 2020 Jun 6
PMID 32498248
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Our double-blind, placebo-controlled study evaluated effects of ubiquinol, the reduced form of coenzyme Q, on mild fatigue in healthy individuals experiencing fatigue in daily life that had continued for more than 1 and less than 6 months. The participants received 100-mg/day (Ubq100; age 44.0 ± 9.8 years; 14 females and 6 males) or 150-mg/day ubiquinol (Ubq150; age 40.4 ± 11.8 years; 14 females and 8 males) or placebo (Plc; age 41.3 ± 13.4 years; 13 females and 7 males) daily for 12 weeks. Measurements of subjective and objective fatigue were conducted by using questionnaires-based fatigue scales/visual analogue scales and autonomic nerve function/biological oxidation index, respectively, prior to the first dosing and every 4 weeks thereafter. Serum ubiquinol level increased three- to four-fold after 4 weeks and remained significantly higher than that after Plc administration throughout the intake period. Although a higher blood level of ubiquinol was observed with Ubq150 than with Ubq100, the difference was not statistically significant. In both Ubq100 and Ubq150 groups, subjective levels of fatigue sensation and sleepiness after cognitive tasks, which consisted of the modified Advanced Trail Making Test, the modified Stroop Color-Word Test, and the Digit Symbol Substitution Test, improved significantly compared with those in the placebo group, suggesting an anti-fatigue effect. The Ubq150 group demonstrated significant improvement compared with the Plc group regarding subjective level of relaxation after task, sleepiness before and after task, motivation for task, and serum level of oxidative stress. Correlation analysis between blood level of ubiquinol and each evaluated effect suggested a positive relationship with relaxation after task, motivation for cognitive task, and parasympathetic activity. The results of the study suggest that ubiquinol intake relieves mild fatigue in healthy individuals.

Citing Articles

Nutrient Therapy for the Improvement of Fatigue Symptoms.

Barnish M, Sheikh M, Scholey A Nutrients. 2023; 15(9).

PMID: 37432282 PMC: 10181316. DOI: 10.3390/nu15092154.


Effectiveness of Coenzyme Q10 Supplementation for Reducing Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Tsai I, Hsu C, Chang C, Tseng P, Chang K Front Pharmacol. 2022; 13:883251.

PMID: 36091835 PMC: 9449413. DOI: 10.3389/fphar.2022.883251.


Association between the total amount of electromagnetic cortical neuronal activity and a decline in motivation.

Ishii A, Matsuo T, Yoshikawa T Physiol Rep. 2021; 9(18):e15028.

PMID: 34558220 PMC: 8461028. DOI: 10.14814/phy2.15028.

References
1.
Malliani A, Pagani M, Lombardi F, Cerutti S . Cardiovascular neural regulation explored in the frequency domain. Circulation. 1991; 84(2):482-92. DOI: 10.1161/01.cir.84.2.482. View

2.
Furukawa T, Kawakami N, Saitoh M, Ono Y, Nakane Y, Nakamura Y . The performance of the Japanese version of the K6 and K10 in the World Mental Health Survey Japan. Int J Methods Psychiatr Res. 2008; 17(3):152-8. PMC: 6878390. DOI: 10.1002/mpr.257. View

3.
Watanabe K, Nozaki S, Goto M, Kaneko K, Hayashinaka E, Irie S . PET imaging of C-labeled coenzyme Q: Comparison of biodistribution between [C]ubiquinol-10 and [C]ubiquinone-10. Biochem Biophys Res Commun. 2019; 512(3):611-615. DOI: 10.1016/j.bbrc.2019.03.073. View

4.
Morris G, Anderson G, Maes M . Hypothalamic-Pituitary-Adrenal Hypofunction in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) as a Consequence of Activated Immune-Inflammatory and Oxidative and Nitrosative Pathways. Mol Neurobiol. 2016; 54(9):6806-6819. DOI: 10.1007/s12035-016-0170-2. View

5.
Appel M, Berger R, Saul J, Smith J, Cohen R . Beat to beat variability in cardiovascular variables: noise or music?. J Am Coll Cardiol. 1989; 14(5):1139-48. DOI: 10.1016/0735-1097(89)90408-7. View